LluÃ-s Mont,, Fesc, Fehra

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6279036/publications.pdf

Version: 2024-02-01

427 papers	43,181 citations	5574 82 h-index	2448 197 g-index
463 all docs	463 docs citations	463 times ranked	22265 citing authors

#	Article	IF	Citations
1	Accuracy of standard bipolar amplitude voltage thresholds to identify late potential channels in ventricular tachycardia ablation. Journal of Interventional Cardiac Electrophysiology, 2023, 66, 15-25.	1.3	5
2	A programme for early diagnosis of atrial fibrillation: a multi-centre study in primary care. Family Practice, 2022, 39, 99-105.	1.9	1
3	Cardiovascular magnetic resonance determinants of ventricular arrhythmic events after myocardial infarction. Europace, 2022, 24, 938-947.	1.7	15
4	Late gadolinium enhancementâ€MRI determines definite lesion formation most accurately at 3 months post ablation compared to later time points. PACE - Pacing and Clinical Electrophysiology, 2022, 45, 72-82.	1.2	10
5	Development and validation of a risk score for predicting pericardial effusion in patients undergoing leadless pacemaker implantation: experience with the Micra transcatheter pacemaker. Europace, 2022, 24, 1119-1126.	1.7	25
6	Septal flash correction with Hisâ€Purkinje pacing predicts echocardiographic response in resynchronization therapy. PACE - Pacing and Clinical Electrophysiology, 2022, 45, 374-383.	1.2	4
7	MRI-Detected Brain Lesions and Cognitive Function in Patients With Atrial Fibrillation Undergoing Left Atrial Catheter Ablation in the Randomized AXAFA-AFNET 5 Trial. Circulation, 2022, 145, 906-915.	1.6	12
8	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac diseases. Europace, 2022, 24, 1307-1367.	1.7	108
9	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the State of Genetic Testing for Cardiac Diseases. Heart Rhythm, 2022, 19, e1-e60.	0.7	78
10	Ablation Lesion Assessment with MRI. Arrhythmia and Electrophysiology Review, 2022, 11, e02.	2.4	9
11	European Heart Rhythm Association (<scp>EHRA</scp>)/Heart Rhythm Society (<scp>HRS</scp>)/Asia Pacific Heart Rhythm Society (<scp>APHRS</scp>)/Latin American Heart Rhythm Society (<scp>LAHRS</scp>) Expert Consensus Statement on the state of genetic testing for cardiac diseases. Journal of Arrhythmia, 2022, 38, 491-553.	1.2	24
12	Late Potential Abolition in Ventricular Tachycardia Ablation. American Journal of Cardiology, 2022, 174, 53-60.	1.6	6
13	Improved procedural workflow for catheter ablation of paroxysmal AF with highâ€density mapping system and advanced technology: Rationale and study design of a multicenter international study. Clinical Cardiology, 2022, , .	1.8	1
14	Conduction system pacing vs. biventricular pacing in patients with ventricular dysfunction and AV block. PACE - Pacing and Clinical Electrophysiology, 2022, , .	1.2	7
15	Recommendations for participation in leisure-time physical activity and competitive sports of patients with arrhythmias and potentially arrhythmogenic conditions. Part 2: ventricular arrhythmias, channelopathies, and implantable defibrillators. Europace, 2021, 23, 147-148.	1.7	47
16	Premature ventricular complex site of origin and ablation outcomes in patients with prior myocardial infarction. Heart Rhythm, 2021, 18, 27-33.	0.7	7
17	Arrhythmogenic substrate detection in chronic ischaemic patients undergoing ventricular tachycardia ablation using multidetector cardiac computed tomography: compared evaluation with cardiac magnetic resonance. Europace, 2021, 23, 82-90.	1.7	10
18	Periprocedural anticoagulation in the uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation (ELIMINATE-AF) trial. Europace, 2021, 23, 65-72.	1.7	2

#	Article	IF	Citations
19	Accuracy of left atrial fibrosis detection with cardiac magnetic resonance: correlation of late gadolinium enhancement with endocardial voltage and conduction velocity. Europace, 2021, 23, 380-388.	1.7	52
20	2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. European Heart Journal, 2021, 42, 17-96.	2.2	830
21	2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal, 2021, 42, 373-498.	2.2	5,583
22	Reduction in new cardiac electronic device implantations in Catalonia during COVID-19. Europace, 2021, 23, 456-463.	1.7	25
23	Optimized singleâ€point left ventricular pacing leads to improved resynchronization compared with multipoint pacing. PACE - Pacing and Clinical Electrophysiology, 2021, 44, 519-527.	1.2	2
24	The plus and pure left bundle branch pacing. Europace, 2021, 23, 1325-1325.	1.7	1
25	Proximity to the descending aorta predicts regional fibrosis in the adjacent left atrial wall: aetiopathogenic and prognostic implications. Europace, 2021, 23, 1559-1567.	1.7	9
26	The imperative of consistency and proficiency in cardiac devices implant skills training. Open Heart, 2021, 8, e001629.	2.3	3
27	Behavior of AV synchrony pacing mode in a leadless pacemaker during variable AV conduction and arrhythmias. Journal of Cardiovascular Electrophysiology, 2021, 32, 1947-1957.	1.7	5
28	Is cardiac magnetic resonance imaging a game changer in re-ablation of atrial fibrillation?â€"Authorsâ€™ reply. Europace, 2021, 23, 1508-1509.	1.7	0
29	Prediction of stroke risk based on left atrial appendage morphology: from pareidolia to artificial intelligence. International Journal of Cardiovascular Imaging, 2021, 37, 2529-2531.	1.5	0
30	Cardiac magnetic resonance to predict recurrences after ventricular tachycardia ablation: septal involvement, transmural channels, and left ventricular mass. Europace, 2021, 23, 1437-1445.	1.7	12
31	Cardiac Resynchronization Therapy Response Is Equalized in Men and Women byÂElectricalÂOptimization. JACC: Clinical Electrophysiology, 2021, 7, 1400-1409.	3.2	2
32	Ventricular tachycardia burden reduction after substrate ablation: Predictors of recurrence. Heart Rhythm, 2021, 18, 896-904.	0.7	20
33	Novel concepts in atrial fibrillation ablationâ€"breaking the tradeâ€off between efficacy and safety. Journal of Arrhythmia, 2021, 37, 904-911.	1.2	8
34	Assessment of primary prevention patients receiving an ICD â€“ Systematic evaluation of ATP: APPRAISE ATP. Heart Rhythm O2, 2021, 2, 405-411.	1.7	4
35	AV junction ablation and cardiac resynchronization for patients with permanent atrial fibrillation and narrow QRS: the APAF-CRT mortality trial. European Heart Journal, 2021, 42, 4731-4739.	2.2	111
36	Scar channels in cardiac magnetic resonance to predict appropriate therapies in primary prevention. Heart Rhythm, 2021, 18, 1336-1343.	0.7	30

#	Article	IF	Citations
37	Nonâ€invasive isthmus identification of complex arrhythmias in congenital heart disease. Journal of Arrhythmia, 2021, 37, 1562-1566.	1.2	0
38	Gain in real-world cardiac resynchronization therapy efficacy with SyncAV dynamic optimization: Heart failure hospitalizations and costs. Heart Rhythm, 2021, 18, 1577-1585.	0.7	17
39	Dynamic risk assessment to improve quality of care in patients with atrial fibrillation: the 7th AFNET/EHRA Consensus Conference. Europace, 2021, 23, 329-344.	1.7	38
40	Is multipoint pacing superior to optimized singleâ€point pacing?. Journal of Cardiovascular Electrophysiology, 2021, 32, 3279-3279.	1.7	0
41	Left Bundle Branch Block. Cardiac Electrophysiology Clinics, 2021, 13, 671-684.	1.7	7
42	Atrioventricular Synchronous Pacing Using a Leadless Ventricular Pacemaker. JACC: Clinical Electrophysiology, 2020, 6, 94-106.	3.2	144
43	The role of clinical assessment and electrophysiology study in Brugada syndrome patients with syncope. American Heart Journal, 2020, 220, 213-223.	2.7	15
44	Permanent phrenic paralysis after cryoablation of atrial fibrillation. Europace, 2020, 22, 337-337.	1.7	0
45	Cryoballoon vs. radiofrequency lesions as detected by late-enhancement cardiac magnetic resonance after ablation of paroxysmal atrial fibrillation: a caseâ€“control study. Europace, 2020, 22, 382-387.	1.7	11
46	Verification of threshold for image intensity ratio analyses of late gadolinium enhancement magnetic resonance imaging of left atrial fibrosis in 1.5T scans. International Journal of Cardiovascular Imaging, 2020, 36, 513-520.	1.5	17
47	Advanced interatrial block: A predictor of covert atrial fibrillation in embolic stroke of undetermined source. Journal of Electrocardiology, 2020, 58, 113-118.	0.9	16
48	Magnetic resonance-guided re-ablation for atrial fibrillation is associated with a lower recurrence rate: a caseâ€“control study. Europace, 2020, 22, 1805-1811.	1.7	18
49	Magnetic Resonance Imaging-Guided Fibrosis Ablation for the Treatment of Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008707.	4.8	44
50	Changes in quality of life, cognition and functional status following catheter ablation of atrial fibrillation. Heart, 2020, 106, 1919-1926.	2.9	17
51	Predictors of atrial mechanical sensing and atrioventricular synchrony with a leadless ventricular pacemaker: Results from the MARVEL 2 Study. Heart Rhythm, 2020, 17, 2037-2045.	0.7	36
52	Randomized study defining the optimum target interlesion distance in ablation index-guided atrial fibrillation ablation. Europace, 2020, 22, 1480-1486.	1.7	25
53	Predictors of recurrence of atrial fibrillation within the first 3 months after ablation. Europace, 2020, 22, 1337-1344.	1.7	21
54	Safety and Outcomes of Ventricular Tachycardia Substrate Ablation During Sinus Rhythm. JACC: Clinical Electrophysiology, 2020, 6, 1435-1448.	3.2	23

#	Article	IF	Citations
55	Left Bundle Branch Pacing. JACC: Case Reports, 2020, 2, 2225-2229.	0.6	3
56	How to best assess ablation lesion formation with late gadolinium enhancement MRI. Journal of Cardiovascular Electrophysiology, 2020, 31, 3067-3068.	1.7	0
57	Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. New England Journal of Medicine, 2020, 383, 1305-1316.	27.0	1,071
58	Ventricular arrhythmia risk is associated with myocardial scar but not with response to cardiac resynchronization therapy. Europace, 2020, 22, 1391-1400.	1.7	15
59	Atrial fibrillation drivers mapping: should I burn or should I go?. Europace, 2020, 22, 843-844.	1.7	0
60	Automatic Detection of Slow Conducting Channels during Substrate Ablation of Scar-Related Ventricular Arrhythmias. Journal of Interventional Cardiology, 2020, 2020, 1-13.	1.2	2
61	Sex differences in catheter ablation of atrial fibrillation: results from AXAFA-AFNET 5. Europace, 2020, 22, 1026-1035.	1.7	26
62	In silico pace-mapping: prediction of left vs. right outflow tract origin in idiopathic ventricular arrhythmias with patient-specific electrophysiological simulations. Europace, 2020, 22, 1419-1430.	1.7	10
63	Ventricular scar channel entrances identified by new wideband cardiac magnetic resonance sequence to guide ventricular tachycardia ablation in patients with cardiac defibrillators. Europace, 2020, 22, 598-606.	1.7	28
64	A validation study of intraoperative performance metrics for training novice cardiac resynchronization therapy implanters. International Journal of Cardiology, 2020, 307, 48-54.	1.7	12
65	Impact of cryoballoon applications on lesion gaps detected by magnetic resonance after pulmonary vein isolation. Journal of Cardiovascular Electrophysiology, 2020, 31, 638-646.	1.7	3
66	Very high pacing thresholds during longâ€term followâ€up predicted by a combination of implant pacing threshold and impedance in leadless transcatheter pacemakers. Journal of Cardiovascular Electrophysiology, 2020, 31, 868-874.	1.7	20
67	Fast Quasi-Conformal Regional Flattening of the Left Atrium. IEEE Transactions on Visualization and Computer Graphics, 2020, 26, 2591-2602.	4.4	9
68	Epicardial ablation of ventricular tachycardia via the aortic cusps in ischemic cardiomyopathy. Revista Espanola De Cardiologia (English Ed), 2020, 73, 685-687.	0.6	0
69	Subcutaneous implantable cardioverter-defibrillator infection affecting deep tissues: is it always mandatory to remove the device?. Europace, 2020, 22, 776-776.	1.7	0
70	Long-term outcomes of ventricular tachycardia substrate ablation incorporating hidden slow conduction analysis. Heart Rhythm, 2020, 17, 1696-1703.	0.7	12
71	Endurance Exercise and Atrial Fibrillation. , 2020, , 659-681.		1
72	From Diagnosis of Cardiac Device Infection to Complete Extraction of the System. , 2020, , 95-108.		0

#	Article	IF	Citations
73	Influence of myocardial scar on the response to frequent premature ventricular complex ablation. Heart, 2019, 105, heartjnl-2018-313452.	2.9	16
74	Cardiac magnetic resonance based ablation procedures: ready for take-off?. Europace, 2019, 21, 5-6.	1.7	2
75	European Heart Rhythm Association (EHRA) consensus document on management of arrhythmias and cardiac electronic devices in the critically ill and post-surgery patient, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa (CASSA), and Latin American Heart Rhythm Society (LAHRS). Europace, 2019, 21, 7-8.	1.7	72
76	Prediction of premature ventricular complex origin in left vs. right ventricular outflow tract: a novel anatomical imaging approach. Europace, 2019, 21, 147-153.	1.7	5
77	Endurance training in young athletes: What happens in childhood, stays in childhood?. European Journal of Preventive Cardiology, 2019, 26, 1998-2000.	1.8	3
78	Atrial high-rate episodes: prevalence, stroke risk, implications for management, and clinical gaps in evidence. Europace, 2019, 21, 1459-1467.	1.7	45
79	Aortic remodelling induced by obstructive apneas is normalized with mesenchymal stem cells infusion. Scientific Reports, 2019, 9, 11443.	3.3	13
80	Frequent premature ventricular complexes and normal ejection fraction: to treat or not to treat?. Heart, 2019, 105, 1386-1387.	2.9	2
81	Programming Pacemakers to Reduce and Terminate Atrial Fibrillation. Current Cardiology Reports, 2019, 21, 127.	2.9	6
82	Reproducibility and accuracy of late gadolinium enhancement cardiac magnetic resonance measurements for the detection of left atrial fibrosis in patients undergoing atrial fibrillation ablation procedures. Europace, 2019, 21, 724-731.	1.7	31
83	Development and external validation of predictive models for prevalent and recurrent atrial fibrillation: a protocol for the analysis of the CATCH ME combined dataset. BMC Cardiovascular Disorders, 2019, 19, 120.	1.7	10
84	Management of anticoagulation in patients undergoing leadless pacemaker implantation. Heart Rhythm, 2019, 16, 1849-1854.	0.7	12
85	Diagnosisâ€toâ€ablation time in atrial fibrillation: A modifiable factor relevant to clinical outcome. Journal of Cardiovascular Electrophysiology, 2019, 30, 1483-1490.	1.7	24
86	Safety and usefulness of a second Micra transcatheter pacemaker implantation after battery depletion. Europace, 2019, 21, 885-885.	1.7	7
87	LGE-MRI Characterization of Left Atrial Fibrosis: a Tool to Establish Prognosis and Guide Atrial Fibrillation Ablation. Current Cardiovascular Risk Reports, 2019, 13, 1.	2.0	2
88	International expert consensus on a scientific approach to training novice cardiac resynchronization therapy implanters using performance quality metrics. International Journal of Cardiology, 2019, 289, 63-69.	1.7	12
89	Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial. European Heart Journal, 2019, 40, 3013-3021.	2.2	125
90	Electrocardiographic optimization techniques in resynchronization therapy. Europace, 2019, 21, 1286-1296.	1.7	15

#	Article	IF	Citations
91	Intensive recreational athletes in the prospective multinational ICD Sports Safety Registry: Results from the European cohort. European Journal of Preventive Cardiology, 2019, 26, 764-775.	1.8	32
92	Thoracoscopic vs. catheter ablation for atrial fibrillation: long-term follow-up of the FAST randomized trial. Europace, 2019, 21, 746-753.	1.7	39
93	Thoracoscopic maze: yes, we can, but should we?. Europace, 2019, 21, 838-839.	1.7	1
94	Failure-free survival of the Riata implantable cardioverter-defibrillator lead after a very long-term follow-up. Indian Pacing and Electrophysiology Journal, 2019, 19, 140-144.	0.6	1
95	EHRA White Paper: knowledge gaps in arrhythmia managementâ€"status 2019. Europace, 2019, 21, 993-994.	1.7	40
96	Cabins, castles, and constant hearts: rhythm control therapy in patients with atrial fibrillation. European Heart Journal, 2019, 40, 3793-3799c.	2.2	60
97	Undetected displacement of a subcutaneous implantable cardioverter-defibrillator lead. importance of performing a chest X-ray during the first weeks post-implant: a case report. European Heart Journal - Case Reports, 2019, 3, 1-5.	0.6	0
98	T-wave inversion in young athletes: Should we check their bones or their identity card? The quest for precision medicine. European Journal of Preventive Cardiology, 2019, 26, 638-640.	1.8	2
99	Determining the best approach to reduce the impact of exercise-induced atrial fibrillation: prevention, screening, or symptom-based treatment?. Expert Review of Cardiovascular Therapy, 2019, 17, 19-29.	1.5	1
100	Effect of PR interval and pacing mode on persistent atrial fibrillation incidence in dual chamber pacemaker patients: a sub-study of the international randomized MINERVA trial. Europace, 2019, 21, 636-644.	1.7	20
101	ACE2 and ACE in acute and chronic rejection after human heart transplantation. International Journal of Cardiology, 2019, 275, 59-64.	1.7	10
102	Inappropriate Shock Due to Air Entrapment in the Pocket of a Subcutaneous Implantable Cardioverter-defibrillator. Revista Espanola De Cardiologia (English Ed), 2019, 72, 79-81.	0.6	2
103	Exercise and atrial fibrillation: how health turns harm, and how to turn it back. Minerva Cardioangiologica, 2019, 67, 411-424.	1.2	7
104	Treatment of atrial fibrillation in patients with enhanced sympathetic tone by pulmonary vein isolation or pulmonary vein isolation and renal artery denervation: clinical background and study design. Clinical Research in Cardiology, 2018, 107, 539-547.	3.3	12
105	Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATEâ€AF study.. Clinical Cardiology, 2018, 41, 440-449.	1.8	12
106	Left atrial geometry and outcome of atrial fibrillation ablation: results from the multicentre LAGO-AF study. European Heart Journal Cardiovascular Imaging, 2018, 19, 1002-1009.	1.2	45
107	Improvement of Reverse RemodelingÂUsing Electrocardiogram Fusion-Optimized Intervals in CardiacÂResynchronization Therapy. JACC: Clinical Electrophysiology, 2018, 4, 181-189.	3.2	64
108	Validity of the Polar V800 monitor for measuring heart rate variability in mountain running route conditions. European Journal of Applied Physiology, 2018, 118, 669-677.	2.5	84

#	Article	IF	Citations
109	Integrating new approaches to atrial fibrillation management: the 6th AFNET/EHRA Consensus Conference. Europace, 2018, 20, 395-407.	1.7	95
110	Postprocedural LGEâ€CMR comparison of laser and radiofrequency ablation lesions after pulmonary vein isolation. Journal of Cardiovascular Electrophysiology, 2018, 29, 1065-1072.	1.7	15
111	Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation. European Heart Journal, 2018, 39, 2942-2955.	2.2	181
112	Impact of left atrial volume, sphericity, and fibrosis on the outcome of catheter ablation for atrial fibrillation. Journal of Cardiovascular Electrophysiology, 2018, 29, 740-746.	1.7	30
113	Multielectrode vs. point-by-point mapping for ventricular tachycardia substrate ablation: a randomized study. Europace, 2018, 20, 512-519.	1.7	49
114	Elucidation of hidden slow conduction by double ventricular extrastimuli: a method for further arrhythmic substrate identification in ventricular tachycardia ablation procedures. Europace, 2018, 20, 337-346.	1.7	38
115	Scar Characterization to Predict Life-Threatening Arrhythmic Events andÂSudden Cardiac Death in Patients With Cardiac Resynchronization Therapy. JACC: Cardiovascular Imaging, 2018, 11, 561-572.	5.3	111
116	The FIRE AND ICE Trial: What We Know, What We Can Still Learn, and What We Need to Address in the Future. Journal of the American Heart Association, 2018, 7, e010777.	3.7	17
117	Delayed Gadolinium Enhancement Magnetic Resonance Imaging Detected Anatomic Gap Length in Wide Circumferential Pulmonary Vein Ablation Lesions Is Associated With Recurrence of Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2018, 11, e006659.	4.8	28
118	Response to the letter to the editor on â€œImpact of left atrial volume, sphericity, and fibrosis on the outcome of catheter ablation for atrial fibrillationâ€• Journal of Cardiovascular Electrophysiology, 2018, 29, E15.	1.7	0
119	Selection of the Best of 2017 in Catheter Ablation. Revista Espanola De Cardiologia (English Ed), 2018, 71, 303-304.	0.6	0
120	Inâ€vivo compatibility between pacemakers and dental equipment. European Journal of Oral Sciences, 2018, 126, 307-315.	1.5	8
121	Atrial Fibrillation in Athletes. , 2018, , 241-256.		0
122	Accelerometer-based atrioventricular synchronous pacing with a ventricular leadless pacemaker: Results from the Micra atrioventricular feasibility studies. Heart Rhythm, 2018, 15, 1363-1371.	0.7	116
123	A randomized controlled trial of atrioventricular junction ablation and cardiac resynchronization therapy in patients with permanent atrial fibrillation and narrow QRS. European Heart Journal, 2018, 39, 3999-4008.	2.2	123
124	Mini-electrodes help identifying hidden slow conduction during ventricular tachycardia substrate ablation. Journal of Electrocardiology, 2018, 51, 1011-1013.	0.9	0
125	Preferential regional distribution of atrial fibrosis in posterior wall around left inferior pulmonary vein as identified by late gadolinium enhancement cardiac magnetic resonance in patients with atrial fibrillation. Europace, 2018, 20, 1959-1965.	1.7	47
126	VT ablation and survival: A solved question?. International Journal of Cardiology, 2018, 267, 118-119.	1.7	0

#	Article	IF	Citations
127	Pre-participation cardiovascular evaluation for athletic participants to prevent sudden death: Position paper from the EHRA and the EACPR, branches of the ESC. Endorsed by APHRS, HRS, and SOLAECE. Europace, 2017, 19, euw243.	1.7	86
128	Use of delayed-enhancement magnetic resonance imaging for fibrosis detection in the atria: a review. Europace, 2017, 19, euw053.	1.7	61
129	Left ventricular dysfunction is related to the presence and extent of a septal flash in patients with right ventricular pacing. Europace, 2017, 19, euw020.	1.7	19
130	Identification of the potentially arrhythmogenic substrate in the acute phase of ST-segment elevation myocardial infarction. Heart Rhythm, 2017, 14, 592-598.	0.7	11
131	Respuesta. Medicina ClÃnica, 2017, 148, 96.	0.6	0
132	SelecciÃ³n de lo mejor del aÃ±o 2016 en estimulaciÃ³n cardiaca: estimulaciÃ³n sinÂcables. Revista Espanola De Cardiologia, 2017, 70, 62-63.	1.2	0
133	Comentarios a la guÃa ESC 2016 sobre el diagnÃ³stico y tratamiento de la fibrilaciÃ³n auricular. Revista Espanola De Cardiologia, 2017, 70, 2-8.	1.2	11
134	The Changing Landscape for StrokeÂPrevention in AF. Journal of the American College of Cardiology, 2017, 69, 777-785.	2.8	244
135	Atrial fibrillation progression: How sick is the atrium?. Heart Rhythm, 2017, 14, 808-809.	0.7	7
136	Presyncopal episodes after implantation of dual-chamber pacemaker programmed in SafeR pacing mode. Europace, 2017, 19, 807-807.	1.7	2
137	A leadless pacemaker in the real-world setting: The Micra Transcatheter Pacing System Post-Approval Registry. Heart Rhythm, 2017, 14, 1375-1379.	0.7	251
138	Impact of operator experience and training strategy on procedural outcomes with leadless pacing: Insights from the Micra Transcatheter Pacing Study. PACE - Pacing and Clinical Electrophysiology, 2017, 40, 834-842.	1.2	26
139	Cardiac Resynchronization Therapy. Heart Failure Clinics, 2017, 13, 233-240.	2.1	14
140	Atrial antitachycardia pacing and atrial remodeling: A substudy of the international, randomized MINERVA trial. Heart Rhythm, 2017, 14, 1476-1484.	0.7	12
141	Correlation between functional electrical gaps identified by ultrahigh-density mapping and by late gadolinium enhancement cardiac magnetic resonance in repeat atrial fibrillation procedure. HeartRhythm Case Reports, 2017, 3, 282-285.	0.4	3
142	Severity of structural and functional right ventricular remodeling depends on training load in an experimental model of endurance exercise. American Journal of Physiology - Heart and Circulatory Physiology, 2017, 313, H459-H468.	3.2	29
143	Extensive atrial fibrosis assessed by late gadolinium enhancement cardiovascular magnetic resonance associated with advanced interatrial block electrocardiogram pattern. Europace, 2017, 19, 377-377.	1.7	31
144	Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation. Europace, 2017, 19, 132-138.	1.7	32

#	Article	IF	Citations
145	Preparticipation cardiovascular evaluation for athletic participants to prevents sudden death: authorâ€™s reply. Europace, 2017, 19, 883-883.	1.7	30
146	Left atrial fibrosis quantification by late gadolinium-enhanced magnetic resonance: a new method to standardize the thresholds for reproducibility. Europace, 2017, 19, 1272-1279.	1.7	103
147	Cardiovascular Benefits of Moderate Exercise Training in Marfan Syndrome: Insights From an Animal Model. Journal of the American Heart Association, 2017, 6, .	3.7	39
148	Patients With Brugada Syndrome and Implanted Cardioverter-Defibrillators. Journal of the American College of Cardiology, 2017, 70, 1991-2002.	2.8	34
149	Persistent atrial fibrillation vs paroxysmal atrial fibrillation: differences in management. Expert Review of Cardiovascular Therapy, 2017, 15, 601-618.	1.5	41
150	Cardiac magnetic resonanceâ€“aided scar dechanneling: Influence on acute and long-term outcomes. Heart Rhythm, 2017, 14, 1121-1128.	0.7	148
151	Clinical recognition of pure premature ventricular complex-induced cardiomyopathy at presentation. Heart Rhythm, 2017, 14, 1864-1870.	0.7	38
152	Diagnosis, pathophysiology, and management of exercise-induced arrhythmias. Nature Reviews Cardiology, 2017, 14, 88-101.	13.7	86
153	Pre-participation cardiovascular evaluation for athletic participants to prevent sudden death: Position paper from the EHRA and the EACPR, branches of the ESC. Endorsed by APHRS, HRS, and SOLAECE. European Journal of Preventive Cardiology, 2017, 24, 41-69.	1.8	181
154	Rate adaptive pacing in an intracardiac pacemaker. Heart Rhythm, 2017, 14, 200-205.	0.7	21
155	Novel Computational Analysis of Left Atrial Anatomy Improves Prediction of Atrial Fibrillation Recurrence after Ablation. Frontiers in Physiology, 2017, 8, 68.	2.8	52
156	Standardised Framework to Study the Influence of Left Atrial RF Catheter Ablation Parameters on Permanent Lesion Formation. Lecture Notes in Computer Science, 2017, , 96-105.	1.3	0
157	Long-term benefit of first-line peri-implantable cardioverterâ€“defibrillator implant ventricular tachycardia-substrate ablation in secondary prevention patients. Europace, 2016, 19, euw096.	1.7	7
158	Differential atrial performance at rest and exercise in athletes: Potential trigger for developing atrial dysfunction?. Scandinavian Journal of Medicine and Science in Sports, 2016, 26, 1444-1454.	2.9	30
159	Left Atrial Geometry Improves Risk Prediction of Thromboembolic Events in Patients With Atrial Fibrillation. Journal of Cardiovascular Electrophysiology, 2016, 27, 804-810.	1.7	38
160	Substrate modification or ventricular tachycardia induction, mapping, and ablation as the first step? A randomized study. Heart Rhythm, 2016, 13, 1589-1595.	0.7	57
161	Status of cardiac resynchronization therapy in Catalonia, Spain: Results of the prospective multicentric study TRC-CAT. Medicina ClÃnica (English Edition), 2016, 146, 423-428.	0.2	1
162	Utility of galectin-3 in predicting post-infarct remodeling after acute myocardial infarction based on extracellular volume fraction mapping. International Journal of Cardiology, 2016, 223, 458-464.	1.7	19

#	Article	IF	Citations
163	What have we learned of ablation procedures for atrial fibrillation?. Journal of Internal Medicine, 2016, 279, 439-448.	6.0	4
164	Molecular disturbance underlies to arrhythmogenic cardiomyopathy induced by transgene content, age and exercise in a truncated PKP2 mouse model. Human Molecular Genetics, 2016, 25, 3676-3688.	2.9	23
165	Safety, long-term outcomes and predictors of recurrence after first-line combined endoepicardial ventricular tachycardia substrate ablation in arrhythmogenic cardiomyopathy. Impact of arrhythmic substrate distribution pattern. A prospective multicentre study. Europace, 2016, 19, euw212.	1.7	37
166	Dyssynchronization reduces dynamic obstruction without affecting systolic function in patients with hypertrophic obstructive cardiomyopathy: a pilot study. International Journal of Cardiovascular Imaging, 2016, 32, 1179-1188.	1.5	7
167	Defining the major health modifiers causing atrial fibrillation: a roadmap to underpin personalized prevention and treatment. Nature Reviews Cardiology, 2016, 13, 230-237.	13.7	122
168	Plasma tissue inhibitor of matrix metalloproteinase-1 a predictor of long-term mortality in patients treated with cardiac resynchronization therapy. Europace, 2016, 18, 232-237.	1.7	12
169	Differentiating hypertrophic cardiomyopathy from athlete's heart: An electrocardiographic and echocardiographic approach. Journal of Electrocardiology, 2016, 49, 539-544.	0.9	12
170	Comparison of right ventricular septal pacing and right ventricular apical pacing in patients receiving cardiac resynchronization therapy defibrillators: the SEPTAL CRT Study. European Heart Journal, 2016, 37, 473-483.	2.2	57
171	A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference. Europace, 2016, 18, 37-50.	1.7	121
172	Emerging risk factors and the doseâ€“response relationship between physical activity and lone atrial fibrillation: a prospective caseâ€“control study. Europace, 2016, 18, 57-63.	1.7	115
173	Contact force threshold for permanent lesion formation in atrial fibrillation ablation: A cardiac magnetic resonanceâ€“based study to detect ablation gaps. Heart Rhythm, 2016, 13, 37-45.	0.7	29
174	First clinical evaluation of an atrial haemodynamic sensor lead for automatic optimization of cardiac resynchronization therapy. Europace, 2016, 18, 755-761.	1.7	8
175	Infarct transmurality as a criterion for first-line endo-epicardial substrateâ€“guided ventricular tachycardia ablation in ischemic cardiomyopathy. Heart Rhythm, 2016, 13, 85-95.	0.7	68
176	Deep breathing-triggered atrial fibrillation: An unusual mechanism terminated by focal RF ablation. Indian Pacing and Electrophysiology Journal, 2015, 15, 199-201.	0.6	1
177	Effects of enhanced pacing modalities on health care resource utilization and costs in bradycardia patients: An analysis of the randomized MINERVA trial. Heart Rhythm, 2015, 12, 1192-1200.	0.7	11
178	CardioPulse Articles. European Heart Journal, 2015, 36, 255-264.	2.2	27
179	Early performance of a miniaturized leadless cardiac pacemaker: the Micra Transcatheter Pacing Study. European Heart Journal, 2015, 36, 2510-2519.	2.2	169
180	3D delayed-enhanced magnetic resonance sequences improve conducting channel delineation prior to ventricular tachycardia ablation. Europace, 2015, 17, 938-945.	1.7	110

#	Article	IF	Citations
181	Registro EspaÃ±ol de AblaciÃ³n con CatÃ©ter. XIVÂInforme Oficial de laÂSecciÃ³n deÂElectrofisiologÃa yÂArritmias de laÂSociedad EspaÃ±ola deÂCardiologÃa (2014). Revista Espanola De Cardiologia, 2015, 68, 1127-1137.	1.2	29
182	Left Atrial Tachycardia After Atrial Fibrillation Ablation: Can Magnetic Resonance Imaging Assist the Ablation?. Canadian Journal of Cardiology, 2015, 31, 104.e1-104.e3.	1.7	2
183	Left atrial deformation predicts success of first and second percutaneous atrial fibrillation ablation. Heart Rhythm, 2015, 12, 11-18.	0.7	70
184	Ranolazine in the treatment of atrial fibrillation: Results of the dose-ranging RAFFAELLO (Ranolazine) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.7	63
185	MRI Assessment of Ablationâ€Induced Scarring in Atrial Fibrillation: Analysis from the DECAAF Study. Journal of Cardiovascular Electrophysiology, 2015, 26, 473-480.	1.7	96
186	An easy-to-use, operator-independent, clinical model to predict the left vs. right ventricular outflow tract origin of ventricular arrhythmias. Europace, 2015, 17, 1122-1128.	1.7	16
187	Atrial fibrillation ablation: less is more?: FigureÂ1. European Heart Journal, 2015, 36, 1792-1793.	2.2	2
188	Extraction of Sterile Leads Is the Preferred Approach Rather than Implanting a New Lead. Cardiac Electrophysiology Clinics, 2015, 7, 427-431.	1.7	1
189	EARLY: a pilot study on early diagnosis of atrial fibrillation in a primary healthcare centre. Europace, 2015, 17, 1688-93.	1.7	18
190	Exercise and the heart: the good, the bad, and the ugly. European Heart Journal, 2015, 36, 1445-1453.	2.2	254
191	New-generation atrial antitachycardia pacing (Reactive ATP) is associated with reduced risk of persistent or permanent atrial fibrillation in patients with bradycardia: Results from the MINERVA randomized multicenter international trial. Heart Rhythm, 2015, 12, 1717-1725.	0.7	56
192	Scar Dechanneling. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 326-336.	4.8	200
193	Optimized pacing mode for hypertrophic cardiomyopathy: Impact of ECG fusion during pacing. Heart Rhythm, 2015, 12, 909-916.	0.7	9
194	Impact of earliest activation site location in the septal right ventricular outflow tract for identification of left vs right outflow tract origin of idiopathic ventricular arrhythmias. Heart Rhythm, 2015, 12, 726-734.	0.7	25
195	Ablation of frequent PVC in patients meeting criteria for primary prevention ICD implant: Safety of withholding the implant. Heart Rhythm, 2015, 12, 2434-2442.	0.7	40
196	Exercise, sex and atrial fibrillation: arrhythmogenesis beyond Y-chromosome?. Heart, 2015, 101, 1607-1609.	2.9	9
197	Clinical development of rivaroxaban: emerging new clinical evidences?. Future Cardiology, 2015, 11, 565-583.	1.2	0
198	Cardiac Resynchronization Therapy. Cardiac Electrophysiology Clinics, 2015, 7, 789-796.	1.7	2

#	Article	IF	Citations
199	Letter by Bisbal et al Regarding Article, â€œRepeat Left Atrial Catheter Ablation: Cardiac Magnetic Resonance Prediction of Endocardial Voltage and Gaps in Ablation Lesion Setsâ€• Circulation: Arrhythmia and Electrophysiology, 2015, 8, 753-753.	4.8	4
200	Genetic analysis, in silico prediction, and family segregation in long QT syndrome. European Journal of Human Genetics, 2015, 23, 79-85.	2.8	16
201	Quantification of local changes in myocardial motion by diffeomorphic registration via currents: Application to paced hypertrophic obstructive cardiomyopathy in 2D echocardiographic sequences. Medical Image Analysis, 2015, 19, 203-219.	11.6	5
202	Catheter ablation vs. antiarrhythmic drug treatment of persistent atrial fibrillation: a multicentre, randomized, controlled trial (SARA study). European Heart Journal, 2014, 35, 501-507.	2.2	285
203	Atrial antitachycardia pacing and managed ventricular pacing in bradycardia patients with paroxysmal or persistent atrial tachyarrhythmias: the MINERVA randomized multicentre international trial. European Heart Journal, 2014, 35, 2352-2362.	2.2	111
204	Reversal of spherical remodelling of the left atrium after pulmonary vein isolation: incidence and predictors. Europace, 2014, 16, 840-847.	1.7	23
205	Usefulness of contrast-enhanced cardiac magnetic resonance in identifying the ventricular arrhythmia substrate and the approach needed for ablation. European Heart Journal, 2014, 35, 1316-1326.	2.2	114
206	Exercise and the heart: unmasking Mr Hyde. Heart, 2014, 100, 999-1000.	2.9	10
207	<scp>EAARN</scp> score, a predictive score for mortality in patients receiving cardiac resynchronization therapy based on preâ€•implantation risk factors. European Journal of Heart Failure, 2014, 16, 802-809.	7.1	59
208	Complete atrioventricular block does reduce mortality in patients with atrial fibrillation treated with cardiac resynchronization therapy: reply. European Journal of Heart Failure, 2014, 16, 115-115.	7.1	2
209	Practical ways to reduce radiation dose for patients and staff during device implantations and electrophysiological procedures. Europace, 2014, 16, 946-964.	1.7	242
210	Fusionâ€Optimized Intervals (FOI): A New Method to Achieve the Narrowest QRS for Optimization of the AV and VV Intervals in Patients Undergoing Cardiac Resynchronization Therapy. Journal of Cardiovascular Electrophysiology, 2014, 25, 283-292.	1.7	58
211	Association of Atrial Tissue Fibrosis Identified by Delayed Enhancement MRI and Atrial Fibrillation Catheter Ablation. JAMA - Journal of the American Medical Association, 2014, 311, 498.	7.4	1,114
212	Benefit of Left Atrial Roof Linear Ablation in Paroxysmal Atrial Fibrillation: A Prospective, Randomized Study. Journal of the American Heart Association, 2014, 3, e000877.	3.7	37
213	CMR-Guided Approach to Localize and Ablate Gaps in Repeat AF Ablation Procedure. JACC: Cardiovascular Imaging, 2014, 7, 653-663.	5.3	129
214	The appropriate and justified use of medical radiation in cardiovascular imaging: a position document of the ESC Associations of Cardiovascular Imaging, Percutaneous Cardiovascular Interventions and Electrophysiology. European Heart Journal, 2014, 35, 665-672.	2.2	301
215	'Fight for sinus rhythm, or surrender?'.... European Heart Journal, 2014, 35, 1427-1429.	2.2	1
216	Atrial functional and geometrical remodeling in highly trained male athletes: for better or worse?. European Journal of Applied Physiology, 2014, 114, 1143-1152.	2.5	41

#	Article	IF	Citations
217	Septal flash predicts cardiac resynchronization therapy response in patients with permanent atrial fibrillation. Europace, 2014, 16, 1342-1349.	1.7	17
218	Left atrial size and function by three-dimensional echocardiography to predict arrhythmia recurrence after first and repeated ablation of atrial fibrillation. European Heart Journal Cardiovascular Imaging, 2014, 15, 515-522.	1.2	43
219	Transthoracic epicardial ablation of mitral isthmus for treatment of recurrent perimitral flutter. Heart Rhythm, 2014, 11, 26-33.	0.7	14
220	Use of MRI to guide electrophysiology procedures. Heart, 2014, 100, 1975-1984.	2.9	11
221	Mechanical Abnormalities Detected WithÂConventional Echocardiography AreÂAssociated With Response and Midterm Survival in CRT. JACC: Cardiovascular Imaging, 2014, 7, 969-979.	5.3	55
222	EHRA/HRS/APHRS Expert Consensus on Ventricular Arrhythmias. Heart Rhythm, 2014, 11, e166-e196.	0.7	230
223	EHRA/HRS/APHRS expert consensus on ventricular arrhythmias. Journal of Arrhythmia, 2014, 30, 327-349.	1.2	3
224	Myocardial motion and deformation patterns in an experimental swine model of acute LBBB/CRT and chronic infarct. International Journal of Cardiovascular Imaging, 2014, 30, 875-887.	1.5	12
225	Atrial fibrosis in a chronic murine model of obstructive sleep apnea: mechanisms and prevention by mesenchymal stem cells. Respiratory Research, 2014, 15, 54.	3.6	44
226	Integration of Mechanical, Structural and Electrical Imaging to Understand Response to Cardiac Resynchronization Therapy. Revista Espanola De Cardiologia (English Ed), 2014, 67, 813-821.	0.6	2
227	Sinus rhythm detection of conducting channels and ventricular tachycardia isthmus in arrhythmogenic right ventricular cardiomyopathy. Heart Rhythm, 2014, 11, 747-754.	0.7	44
228	IntegraciÃ³n de la imagen mecÃ¡nica, estructural y elÃ©ctrica para entender la respuesta a la terapia de resincronizaciÃ³n cardiaca. Revista Espanola De Cardiologia, 2014, 67, 813-821.	1.2	6
229	GuÃa de prÃ¡ctica clÃnica de la ESC 2013 sobre estimulaciÃ³n cardiaca y terapia de resincronizaciÃ³n cardiaca. Revista Espanola De Cardiologia, 2014, 67, 58.e1-58.e60.	1.2	4
230	Rapid palpitations: three of a kind?. Netherlands Heart Journal, 2013, 21, 472-472.	0.8	0
231	Rapid palpitations: three of a kind?. Netherlands Heart Journal, 2013, 21, 475-475.	0.8	0
232	EHRA is all of us. Herzschrittmachertherapie Und Elektrophysiologie, 2013, 24, 60-62.	0.8	0
233	Innovations in Heart Rhythm Disturbances: Cardiac Electrophysiology, Arrhythmias, and Cardiac Pacing. Revista Espanola De Cardiologia (English Ed), 2013, 66, 116-123.	0.6	3
234	La presiÃ³n arterial ambulatoria nocturna se asocia al remodelado auricular y la activaciÃ³n neurohormonal en pacientes con fibrilaciÃ³n auricular idiopÃ¡tica. Revista Espanola De Cardiologia, 2013, 66, 458-463.	1.2	9

#	Article	IF	Citations
235	Fragmented QRS as a predictor of arrhythmic events in patients with hypertrophic obstructive cardiomyopathy. Journal of Interventional Cardiac Electrophysiology, 2013, 38, 159-165.	1.3	42
236	Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conference. Europace, 2013, 15, 1540-1556.	1.7	125
237	Effect of Cardiac Resynchronization Therapy on Left Ventricular Diastolic Function: Implications for Clinical Outcome. Journal of Cardiac Failure, 2013, 19, 795-801.	1.7	13
238	Consens per a la prevenciÃ³ de la mort sobtada cardÃaca en els esportistes. Apunts Medicine De L'Esport, 2013, 48, 35-41.	0.5	12
239	Neurohormonal, Structural, and Functional Recovery Pattern After Premature Ventricular Complex Ablation Is Independent of Structural Heart Disease Status in Patients With Depressed LeftÂVentricular Ejection Fraction. Journal of the American College of Cardiology, 2013, 62, 1195-1202.	2.8	99
240	DiagnÃ³stico diferencial entre doble respuesta ventricular y extrasistolia hisiana bigeminada. Respuesta. Revista Espanola De Cardiologia, 2013, 66, 515-516.	1.2	0
241	Differential Diagnosis Between Dual Ventricular Response and Bigeminy Arising From the Bundle of His. Response. Revista Espanola De Cardiologia (English Ed), 2013, 66, 515-516.	0.6	0
242	Nighttime Ambulatory Blood Pressure is Associated With Atrial Remodelling and Neurohormonal Activation in Patients With Idiopathic Atrial Fibrillation. Revista Espanola De Cardiologia (English Ed), 2013, 66, 458-463.	0.6	8
243	Analysis of the arrhythmogenic substrate in human heart failure. Cardiovascular Pathology, 2013, 22, 133-140.	1.6	8
244	ActualizaciÃ³n detallada de las guÃas de la ESC para el manejo de la fibrilaciÃ³n auricular de 2012. Revista Espanola De Cardiologia, 2013, 66, 54.e1-54.e24.	1.2	14
245	Impact of atrial fibrillation-induced tachycardiomyopathy in patients undergoing pulmonary vein isolation. International Journal of Cardiology, 2013, 168, 4093-4097.	1.7	57
246	Doble respuesta ventricular: otra vÃa a la taquicardia supraventricular en fisiologÃa doble del nÃ³dulo. Revista Espanola De Cardiologia, 2013, 66, 145-146.	1.2	6
247	Noncompaction Cardiomyopathy is Associated With Mechanical Dyssynchrony: A Potential Underlying Mechanism for Favorable Response to Cardiac Resynchronization Therapy. Journal of Cardiac Failure, 2013, 19, 80-86.	1.7	10
248	Dual Ventricular Response: Another Road to Supraventricular Tachycardia in Dual Atrioventricular Nodal Physiology. Revista Espanola De Cardiologia (English Ed), 2013, 66, 145-146.	0.6	4
249	Atrial Fibrillation Promotion by Endurance Exercise. Journal of the American College of Cardiology, 2013, 62, 68-77.	2.8	252
250	Left Atrial Sphericity: A New Method to Assess Atrial Remodeling. Impact on the Outcome of Atrial Fibrillation Ablation. Journal of Cardiovascular Electrophysiology, 2013, 24, 752-759.	1.7	127
251	2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: The Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Europace, 2013, 15, 1070-1118.	1.7	908
252	Complete atrioventricular block does not reduce longâ€term mortality in patients with permanent atrial fibrillation treated with cardiac resynchronization therapy. European Journal of Heart Failure, 2013, 15, 1412-1418.	7.1	20

#	Article	IF	Citations
253	Differential clinical characteristics and prognosis of intraventricular conduction defects in patients with chronic heart failure. European Journal of Heart Failure, 2013, 15, 877-884.	7.1	27
254	2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. European Heart Journal, 2013, 34, 2281-2329.	2.2	2,176
255	Three-Dimensional Architecture of Scar and Conducting Channels Based on High Resolution ce-CMR. Circulation: Arrhythmia and Electrophysiology, 2013, 6, 528-537.	4.8	179
256	Posterior Coronary Vein as the Substrate for an Epicardial Accessory Pathway. Indian Pacing and Electrophysiology Journal, 2013, 13, 142-147.	0.6	10
257	Losartan Prevents Heart Fibrosis Induced by Long-Term Intensive Exercise in an Animal Model. PLoS ONE, 2013, 8, e55427.	2.5	47
258	Manifold Learning Characterization of Abnormal Myocardial Motion Patterns: Application to CRT-Induced Changes. Lecture Notes in Computer Science, 2013, , 450-457.	1.3	1
259	Wytyczne ESC dotyczÄ...ce stymulacji serca i terapii resynchronizujÄ...cej w 2013 roku. Kardiologia Polska, 2013, 71, 133-192.	0.6	4
260	Predictors of clinical efficacy of â€˜Ablate and Paceâ€™ therapy in patients with permanent atrial fibrillation. Heart, 2012, 98, 297-302.	2.9	37
261	Improving Safety of Epicardial Ventricular Tachycardia Ablation Using the Scar Dechanneling Technique and the Integration of Anatomy, Scar Components, and Coronary Arteries Into the Navigation System. Circulation, 2012, 125, e466-8.	1.6	15
262	Combined Endocardial and Epicardial Catheter Ablation in Arrhythmogenic Right Ventricular Dysplasia Incorporating Scar Dechanneling Technique. Circulation: Arrhythmia and Electrophysiology, 2012, 5, 111-121.	4.8	189
263	Mapping Data Predictors of a Left Ventricular Outflow Tract Origin of Idiopathic Ventricular Tachycardia With V ‹sub›3‹/sub› Transition and Septal Earliest Activation. Circulation: Arrhythmia and Electrophysiology, 2012, 5, 484-491.	4.8	28
264	Cardiac resynchronization therapy in patients with permanent atrial fibrillation. Is it mandatory to ablate the atrioventricular junction to obtain a good response?. European Journal of Heart Failure, 2012, 14, 635-641.	7.1	33
265	Atrial Fibrillation Catheter Ablation Versus Surgical Ablation Treatment (FAST). Circulation, 2012, 125, 23-30.	1.6	357
266	Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options--a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. Europace, 2012, 14, 8-27.	1.7	193
267	Use of myocardial scar characterization to predict ventricular arrhythmia in cardiac resynchronization therapy. Europace, 2012, 14, 1578-1586.	1.7	71
268	Biventricular / Left Ventricular Pacing in Hypertrophic Obstructive Cardiomyopathy: An Overview. Indian Pacing and Electrophysiology Journal, 2012, 12, 114-123.	0.6	5
269	2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Patient Selection, Procedural Techniques, Patient Management and Follow-up, Definitions, Endpoints, and Research Trial Design: A report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the E. Europace, 2012, 14, 528-606.	1.7	1,497
270	Arrhythmias in the athlete. Herzschrittmachertherapie Und Elektrophysiologie, 2012, 23, 76-81.	0.8	6

#	Article	IF	Citations
271	Improved Outcomes and Complications of Atrial Fibrillation Catheter Ablation Over Time: Learning Curve, Techniques, and Methodology. Revista Espanola De Cardiologia (English Ed), 2012, 65, 131-138.	0.6	11
272	New Evidence, New Controversies: a Critical Review of the European Society of Cardiology 2010 Clinical Practice Guidelines on Atrial Fibrillation. Revista Espanola De Cardiologia (English Ed), 2012, 65, 7-13.	0.6	1
273	Atlas-Based Quantification of Myocardial Motion Abnormalities: Added-Value for Understanding the Effect of Cardiac Resynchronization Therapy. Ultrasound in Medicine and Biology, 2012, 38, 2186-2197.	1.5	8
274	2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Patient Selection, Procedural Techniques, Patient Management and Follow-up, Definitions, Endpoints, and Research Trial Design. Heart Rhythm, 2012, 9, 632-696.e21.	0.7	1,541
275	Displacement of the target ablation site and ventricles during premature ventricular contractions: Relevance for radiofrequency catheter ablation. Heart Rhythm, 2012, 9, 1050-1057.	0.7	16
276	2012 focused update of the ESC Guidelines for the management of atrial fibrillation. Europace, 2012, 14, 1385-1413.	1.7	2,319
277	Assessing reverse remodeling in heart failure patients treated with cardiac resynchronization therapy and its impact on prognosis. Expert Review of Cardiovascular Therapy, 2012, 10, 1437-1448.	1.5	2
278	Atrial fibrillation and atrial flutter in athletes. British Journal of Sports Medicine, 2012, 46, i37-i43.	6.7	72
279	EvoluciÃ³n de la mejora en los resultados y las complicaciones de la ablaciÃ³n por catÃ©ter de la fibrilaciÃ³n auricular: aprendizaje, tÃ©cnicas y metodologÃa. Revista Espanola De Cardiologia, 2012, 65, 131-138.	1.2	28
280	Nuevas evidencias, nuevas controversias: anÃ¡lisis crÃtico de la guÃa de prÃ¡ctica clÃnica sobre fibrilaciÃ³n auricular 2010 de la Sociedad Europea de CardiologÃa. Revista Espanola De Cardiologia, 2012, 65, 7-13.	1.2	26
281	2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management: A registered branch of the European Society of Cardiology (ESC), and the Heart Rhythm Society; and in collaboration with the Heart Failure Society of America (HFSA), the American Society of Echocardiography (ASE), the American Heart Association (AHA), the European Association of Echocardiography (EAE) of the ESC and the Heart		

#	Article	IF	Citations
289	The European Cardiac Resynchronization Therapy Survey: comparison of outcomes between de novo cardiac resynchronization therapy implantations and upgrades. European Journal of Heart Failure, 2011, 13, 974-983.	7.1	91
290	Reply to the Editorâ€"Biventricular pacing in hypertrophic obstructive cardiomyopathy. Heart Rhythm, 2011, 8, e26.	0.7	0
291	Biventricular pacing in hypertrophic obstructive cardiomyopathy: A pilot study. Heart Rhythm, 2011, 8, 221-227.	0.7	34
292	Diferencias de gÃ©nero en el manejo de los pacientes con fibrilaciÃ³n auricular: anÃ¡lisis de base poblacional en un Ã¡rea bÃ¡sica de salud. Revista Espanola De Cardiologia, 2011, 64, 233-236.	1.2	18
293	Sex Differences in the Treatment of Patients With Atrial Fibrillation: Population-Based Study in a Local Health District. Revista Espanola De Cardiologia (English Ed), 2011, 64, 233-236.	0.6	9
294	Comprehensive risk reduction in patients with atrial fibrillation: Emerging diagnostic and therapeutic options. Thrombosis and Haemostasis, 2011, 106, 1012-1019..	3.4	81
295	Pitfalls of Programming Sensing Polarities Using the Coronary Sinus Lead in Biventricular Pacemakers. PACE - Pacing and Clinical Electrophysiology, 2011, 34, e22-5.	1.2	1
296	Bifocal Right Ventricular Resynchronization for the Failing Right Ventricle. PACE - Pacing and Clinical Electrophysiology, 2011, 34, e78-81.	1.2	2
297	Comparison of Hemodynamic versus Dyssynchrony Assessment for Interventricular Delay Optimization with Echocardiography in Cardiac Resynchronization Therapy. PACE - Pacing and Clinical Electrophysiology, 2011, 34, 984-990.	1.2	9
298	Electrocardiographic versus Echocardiographic Optimization of the Interventricular Pacing Delay in Patients Undergoing Cardiac Resynchronization Therapy. Journal of Cardiovascular Electrophysiology, 2011, 22, 1129-1134.	1.7	48
299	Effect of Repeated Radiofrequency Catheter Ablation on Left Atrial Function for the Treatment of Atrial Fibrillation. American Journal of Cardiology, 2011, 108, 1741-1746.	1.6	27
300	Cardiac resynchronization therapy in patients undergoing atrioventricular junction ablation for permanent atrial fibrillation: a randomized trial. European Heart Journal, 2011, 32, 2420-2429.	2.2	241
301	Response to Letters Regarding Article, â€œCardiac Arrhythmogenic Remodeling in a Rat Model of Long-Term Intensive Exercise Trainingâ€. Circulation, 2011, 124, .	1.6	0
302	Integration of 3D Electroanatomic Maps and Magnetic Resonance Scar Characterization Into the Navigation System to Guide Ventricular Tachycardia Ablation. Circulation: Arrhythmia and Electrophysiology, 2011, 4, 674-683.	4.8	153
303	Rationale and current perspective for early rhythm control therapy in atrial fibrillation. Europace, 2011, 13, 1517-1525.	1.7	55
304	Usefulness of transoesophageal echocardiography before circumferential pulmonary vein ablation in patients with atrial fibrillation: is it really mandatory?. Europace, 2011, 13, 486-491.	1.7	48
305	Diagnosis, management, and outcomes of patients with syncope and bundle branch block. European Heart Journal, 2011, 32, 1535-1541.	2.2	115
306	Entrapment of the circular mapping catheter in the mitral valve in two patients undergoing atrial fibrillation ablation. Europace, 2011, 13, 132-133.	1.7	16

#	Article	IF	Citations
307	Decreased likelihood of response to cardiac resynchronization in patients with severe heart failure. European Journal of Heart Failure, 2010, 12, 283-287.	7.1	44
308	Analysis of mRNA from human heart tissue and putative applications in forensic molecular pathology. Forensic Science International, 2010, 203, 99-105.	2.2	38
309	Cardiac resynchronization for New York Heart Association class IV patients: reply. Europace, 2010, 12, 1797-1798.	1.7	0
310	Low efficacy of atrial fibrillation ablation in severe obstructive sleep apnoea patients. Europace, 2010, 12, 1084-1089.	1.7	138
311	Left ventricular systolic dysfunction by itself does not influence outcome of atrial fibrillation ablation. Europace, 2010, 12, 24-29.	1.7	73
312	Efficacy of circumferential pulmonary vein ablation of atrial fibrillation in endurance athletes. Europace, 2010, 12, 30-36.	1.7	109
313	Survival in New York Heart Association class IV heart failure patients treated with cardiac resynchronization therapy compared with patients on optimal pharmacological treatment. Europace, 2010, 12, 1136-1140.	1.7	31
314	Skeletal myoblast implants induce minor propagation delays, but do not promote arrhythmias in the normal swine heart. Europace, 2010, 12, 1637-1644.	1.7	2
315	Plasma tissue inhibitor of matrix metalloproteinaseâ€1 (TIMPâ€1): an independent predictor of poor response to cardiac resynchronization therapy. European Journal of Heart Failure, 2010, 12, 492-498.	7.1	16
316	Circumferential pulmonary vein ablation: Does use of a circular mapping catheter improve results? A prospective randomized study. Heart Rhythm, 2010, 7, 612-618.	0.7	29
317	R-wave peak time at DII: A new criterion for differentiating between wide complex QRS tachycardias. Heart Rhythm, 2010, 7, 922-926.	0.7	112
318	Analysis of temporal delay in myocardial deformation throughout the cardiac cycle: Utility for selecting candidates for cardiac resynchronization therapy. Heart Rhythm, 2010, 7, 1580-1586.	0.7	6
319	Arrhythmias and sport practice. Heart, 2010, 96, 398-405.	2.9	33
320	Endurance Sport Practice and Atrial Fibrillation. Journal of Atrial Fibrillation, 2010, 2, .	0.5	2
321	Endurance Sport Practice and Arrhythmias. , 2010, , 57-72.		0
322	Atlas-Based Quantification of Myocardial Motion Abnormalities: Added-value for the Understanding of CRT Outcome?. Lecture Notes in Computer Science, 2010, , 65-74.	1.3	0
323	Endurance Sport Practice and Atrial Fibrillation. Journal of Atrial Fibrillation, 2010, 3, 288.	0.5	0
324	Six-minute walking test predicts long-term cardiac death in patients who received cardiac resynchronization therapy. Europace, 2009, 11, 338-342.	1.7	30

#	Article	IF	Citations
325	Left Atrial Posterior Wall Isolation Does Not Improve the Outcome of Circumferential Pulmonary Vein Ablation for Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2009, 2, 35-40.	4.8	129
326	Letter by Mont et al Regarding Article, â€œPhysical Activity and Incidence of Atrial Fibrillation in Older Adults: The Cardiovascular Health Studyâ€• Circulation, 2009, 119, e195; author reply e196.	1.6	3
327	Preparation for pacemaker or implantable cardiac defibrillator implants in patients with high risk of thrombo-embolic events: oral anticoagulation or bridging with intravenous heparin? A prospective randomized trial. European Heart Journal, 2009, 30, 1880-1884.	2.2	104
328	Morphology discrimination criterion wavelet improves rhythm discrimination in single-chamber implantable cardioverter-defibrillators: Spanish Register of morphology discrimination criterion wavelet (REMEDIO). Europace, 2009, 11, 727-733.	1.7	26
329	Inappropriate shocks or inappropriate programming? A review of Guidant'sTM reconfirmation algorithm. Europace, 2009, 11, 1120-1122.	1.7	5
330	Electrophysiology: it is time to simplify!. Europace, 2009, 11, 985-986.	1.7	5
331	Midterm 'super-response' to cardiac resynchronization therapy by biventricular pacing with fusion: insights from electro-anatomical mapping. Europace, 2009, 11, 1675-1682.	1.7	47
332	Noninvasive Evaluation of Radiofrequency Lesions in the Human Ventricular Myocardium by Contrast-Enhanced Cardiac Magnetic Resonance. Circulation: Arrhythmia and Electrophysiology, 2009, 2, 208-211.	4.8	7
333	Mechanism of Decrease in Mitral Regurgitation After Cardiac Resynchronization Therapy. Circulation: Cardiovascular Imaging, 2009, 2, 444-450.	2.6	68
334	Electrocardiographic Optimization of Cardiac Resynchronization Devices: Simple, but Not So Simple!. American Journal of Cardiology, 2009, 103, 894.	1.6	2
335	Long-Term Effect of Cardiac Resynchronization Therapy on Functional Mitral Valve Regurgitation. American Journal of Cardiology, 2009, 104, 383-388.	1.6	54
336	Optimization of the Interventricular Delay in Cardiac Resynchronization Therapy Using the QRS Width. American Journal of Cardiology, 2009, 104, 1407-1412.	1.6	39
337	Quantification of Left Ventricular Asynchrony Throughout the Whole Cardiac Cycle with a Computed Algorithm: Application for Optimizing Resynchronization Therapy. Journal of Cardiovascular Electrophysiology, 2009, 20, 1130-1136.	1.7	10
338	Reexcitation mechanisms in epicardial tissue: Role of Ito density heterogeneities and INa inactivation kinetics. Journal of Theoretical Biology, 2009, 259, 850-859.	1.7	16
339	An implantable defibrillator and what else?. European Heart Journal, 2009, 30, 1551-1553.	2.2	0
340	Cardiac Motion Estimation from Intracardiac Electrical Mapping Data: Identifying a Septal Flash in Heart Failure. Lecture Notes in Computer Science, 2009, , 21-29.	1.3	7
341	Left ventricular function and visual phase analysis with equilibrium radionuclide angiography in patients with biventricular device. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 912-921.	6.4	8
342	Left Atrial Contractility is Preserved After Successful Circumferential Pulmonary Vein Ablation in Patients with Atrial Fibrillation. Journal of Cardiovascular Electrophysiology, 2008, 19, 374-379.	1.7	47

#	Article	IF	Citations
343	Fate of Left Atrial Function as Determined by Real-Time Three-Dimensional Echocardiography Study After Radiofrequency Catheter Ablation for the Treatment of Atrial Fibrillation. American Journal of Cardiology, 2008, 101, 1285-1290.	1.6	58
344	Comparison of Benefits and Mortality in Cardiac Resynchronization Therapy in Patients With Atrial Fibrillation Versus Patients in Sinus Rhythm (Results of the Spanish Atrial Fibrillation and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 697 Td (	1.6	80
345	Usefulness of Echo-Guided Cardiac Resynchronization Pacing in Patients Undergoing â€œAblate and Paceâ€•Therapy for Permanent Atrial Fibrillation and Effects of Heart Rate Regularization and Left Ventricular Resynchronizationâ€â€A list of participating institutions and investigators appears in the Appendix.. American Journal of Cardiology, 2008, 102, 854-860.	1.6	3
346	Gender Differences in Clinical Manifestations of Brugada Syndrome. Journal of the American College of Cardiology, 2008, 52, 1567-1573.	2.8	265
347	The MINERVA study design and rationale: A controlled randomized trial to assess the clinical benefit of minimizing ventricular pacing in pacemaker patients with atrial tachyarrhythmias. American Heart Journal, 2008, 156, 445-451.	2.7	24
348	A mutation in the sodium channel is responsible for the association of long QT syndrome and familial atrial fibrillation. Heart Rhythm, 2008, 5, 1434-1440.	0.7	93
349	Physical activity, height, and left atrial size are independent risk factors for lone atrial fibrillation in middle-aged healthy individuals. Europace, 2008, 10, 15-20.	1.7	237
350	Long-term endurance sport practice increases the incidence of lone atrial fibrillation in men: a follow-up study. Europace, 2008, 10, 618-623.	1.7	289
351	Cooled-tip vs. 8 mm-tip catheter for circumferential pulmonary vein ablation: comparison of efficacy, safety, and lesion extension. Europace, 2008, 10, 955-960.	1.7	18
352	Endurance sport practice as a risk factor for atrial fibrillation and atrial flutter. Europace, 2008, 11, 11-17.	1.7	224
353	Corrigendum to 'Physical activity, height, and left atrial size are independent risk factors for lone atrial fibrillation in middle-aged healthy individuals'. Europace, 2008, 10, 388-388.	1.7	1
354	HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Personnel, Policy, Procedures and Follow-Up: A report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Europace, 2008, 11, 132-132.	1.7	4
355	HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Personnel, Policy, Procedures and Follow-Up: A report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation Developed in partnership with the European Heart Rhythm Association (EHRA) and the European Cardiac Arrhythmia Society (ECAS); in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), and the Soci. Europace, 2007, 9, 335-379.	1.7	741
356	Cardiac resynchronization therapy: predictive factors of unsuccessful left ventricular lead implant. European Heart Journal, 2007, 28, 450-456.	2.2	24
357	Pre-procedural predictors of atrial fibrillation recurrence after circumferential pulmonary vein ablation. European Heart Journal, 2007, 28, 836-841.	2.2	351
358	Is there an anatomical substrate for idiopathic paroxysmal atrial fibrillation? A caseâ€“control echocardiographic study. Europace, 2007, 9, 294-298.	1.7	27
359	Predictors of success and effect of biphasic energy on electrical cardioversion in patients with persistent atrial fibrillation. Europace, 2007, 9, 942-946.	1.7	19
360	Characterization of focal right atrial appendage tachycardia. Europace, 2007, 10, 105-109.	1.7	40

#	Article	IF	Citations
361	Impact of anti-tachycardia pacing on atrial fibrillation burden when added on top of preventive pacing algorithms: results of the prevention or termination (POT) trial. Europace, 2007, 10, 28-34.	1.7	30
362	Predictors of arrhythmia recurrence in patients with lone atrial fibrillation. Europace, 2007, 10, 9-14.	1.7	23
363	Optimizing the clinical use of implantable defibrillators in patients with Brugada syndrome. Country Review Ukraine, 2007, 9, I74-I80.	0.8	13
364	Lone atrial fibrillation and sport practice. The no gain without pain history revisited again?. International Journal of Cardiology, 2007, 118, 414-415.	1.7	6
365	Corrigendum to â€œSport practice and the risk of lone atrial fibrillation: A caseâ€“control studyâ€• [International Journal of Cardiology 108/3 (2006) 332â€“337]. International Journal of Cardiology, 2007, 123, 74.	1.7	2
366	HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Personnel, Policy, Procedures and Follow-Up. Heart Rhythm, 2007, 4, 816-861.	0.7	1,258
367	Impact of Implementing Common Guidelines at Different Care Levels in a Healthcare Area on the Improvement of Atrial Fibrillation Treatment. Revista Espanola De Cardiologia (English Ed), 2007, 60, 392-403.	0.6	3
368	Low Exposure Radiation with Conventional Guided Radiofrequency Catheter Ablation in Pregnant Women. PACE - Pacing and Clinical Electrophysiology, 2007, 30, 1299-1302.	1.2	29
369	Electrocardiographic Optimization of Interventricular Delay in Cardiac Resynchronization Therapy: A Simple Method to Optimize the Device. Journal of Cardiovascular Electrophysiology, 2007, 18, 1252-1257.	1.7	57
370	Usefulness of Ventricular Dyssynchrony Measured Using M-Mode Echocardiography to Predict Response to Resynchronization Therapy. American Journal of Cardiology, 2007, 100, 84-89.	1.6	29
371	Pseudoâ€“Atrial Fibrillation, Rare Manifestation of Multiple Anterograde Atrioventricular Nodal Pathways. American Journal of Cardiology, 2007, 100, 154-156.	1.6	12
372	Optimizing the Programation of Cardiac Resynchronization Therapy Devices in Patients With Heart Failure and Left Bundle Branch Block. American Journal of Cardiology, 2007, 100, 1002-1006.	1.6	84
373	EstimulaciÃ³n en la insuficiencia cardiaca congestiva. SituaciÃ³n actual y perspectivas. Revista Espanola De Cardiologia Suplementos, 2007, 7, 102G-125G.	0.2	2
374	Selective segmental ostial ablation and circumferential pulmonary veins ablation. Results of an individualized strategy to cure refractory atrial fibrillation. Journal of Interventional Cardiac Electrophysiology, 2007, 19, 19-27.	1.3	6
375	Single-, dual-, or triple-chamber defibrillators: The simpler the better?. Heart Rhythm, 2006, 3, 1404-1405.	0.7	1
376	Sport practice and the risk of lone atrial fibrillation: A caseâ€“control study. International Journal of Cardiology, 2006, 108, 332-337.	1.7	212
377	Transient endothelial dysfunction is present shortly after cardioversion in patients with lone atrial fibrillation. Thrombosis Research, 2006, 117, 235-240.	1.7	3
378	Incidence of syncope after ICD implantation: low or high?. European Heart Journal, 2006, 27, 2481-2482.	2.2	2

#	Article	IF	Citations
379	Anodal Capture in Cardiac Resynchronization Therapy Implications for Device Programming. PACE - Pacing and Clinical Electrophysiology, 2006, 29, 940-945.	1.2	34
380	Relation of Response to Cardiac Resynchronization Therapy to Left Ventricular Reverse Remodeling. American Journal of Cardiology, 2006, 97, 876-881.	1.6	32
381	Epicardial ablation of syncopal ventricular tachycardia. Utility of the electrocardiogram. Europace, 2006, 8, 338-340.	1.7	3
382	Predictors of Lack of Response to Resynchronization Therapy. American Journal of Cardiology, 2005, 95, 1436-1440.	1.6	212
383	Consenso sobre la terapia de ResincronizaciÃ³n CardÃaca. Revista Espanola De Cardiologia Suplementos, 2005, 5, 3B-11B.	0.2	4
384	Incidence of Pulmonary Vein Stenosis in Patients Submitted to Atrial Fibrillation Ablation: A Comparison of the Selective Segmental Ostial Ablation vs the Circumferential Pulmonary Veins Ablation. Journal of Interventional Cardiac Electrophysiology, 2005, 14, 21-25.	1.3	40
385	Pacemaker selection: time for a rethinking of complex pacing systems. European Heart Journal, 2005, 27, 1126-1127.	2.2	1
386	Electrocardiographic optimization of interventricular delay in cardiac resynchronization therapy: Correlation with echocardiography. Heart Rhythm, 2005, 2, S289.	0.7	1
387	Electrocardiographic Recognition of the Epicardial Origin of Ventricular Tachycardias. Circulation, 2004, 109, 1842-1847.	1.6	335
388	Radiofrequency Catheter Ablation for Arrhythmic Storm in Patients with An Implantable Cardioverter Defibrillator. PACE - Pacing and Clinical Electrophysiology, 2004, 27, 971-975.	1.2	57
389	Short Head-Up Tilt Test Potentiated with Oral Nitroglycerine:. Comparison with a Conventional Test Using Isoproterenol. PACE - Pacing and Clinical Electrophysiology, 2004, 27, 1085-1088.	1.2	9
390	Orthodromic Pacemaker-Mediated Tachycardia in a Biventricular System Without an Atrial Electrode. Journal of Cardiovascular Electrophysiology, 2004, 15, 1100-1102.	1.7	15
391	Predictores de ausencia de mejorÃa clÃnica a medio plazo con la terapia de resincronizaciÃ³n cardÃaca. Revista Espanola De Cardiologia, 2004, 57, 306-312.	1.2	12
392	Predictores de ausencia de mejorÃa clÃnica a medio plazo con la terapia de resincronizaciÃ³n cardÃaca. Revista Espanola De Cardiologia, 2004, 57, 306-312.	1.2	10
393	Comparison of effectiveness of implantable cardioverter defibrillator in patients with idiopathic dilated cardiomyopathy versus those with proved coronary heart disease. American Journal of Cardiology, 2003, 92, 1227-1230.	1.6	3
394	Natural History of Brugada Syndrome:. Journal of Cardiovascular Electrophysiology, 2003, 14, 455-457.	1.7	192
395	Electrical Interference from an Abdominal Muscle Stimulator Unit on an Implantable Cardioverter Defibrillator:. PACE - Pacing and Clinical Electrophysiology, 2003, 26, 1292-1293.	1.2	12
396	Reversibility of Cardiac Abnormalities in Adolescents With Anorexia Nervosa After Weight Recovery. Journal of the American Academy of Child and Adolescent Psychiatry, 2003, 42, 808-813.	0.5	181

#	Article	IF	Citations
397	Nonsurgical transthoracic epicardial radiofrequency ablation. Journal of the American College of Cardiology, 2003, 41, 2036-2043.	2.8	135
398	Endurance athletes: exploring the limits andbeyond. European Heart Journal, 2003, 24, 1469-1470.	2.2	2
399	Surgical Treatment of Pacemaker and Defibrillator Lead Endocarditis. Chest, 2003, 124, 1451-1459.	0.8	237
400	AblaciÃ³n por radiofrecuencia para el tratamiento de la fibrilaciÃ³n auricular focal a travÃ©s de cartografÃa circunferencial y aislamiento segmentario de las venas pulmonares. Revista Espanola De Cardiologia, 2003, 56, 361-367.	1.2	7
401	Anorexia nerviosa: una enfermedad con repercusiones cardÃacas potencialmente letales. Revista Espanola De Cardiologia, 2003, 56, 652-653.	1.2	3
402	Documento de consenso sobre el tratamiento de la fibrilaciÃ³n auricular en los servicios de urgencias hospitalarios. Revista Espanola De Cardiologia, 2003, 56, 801-816.	1.2	4
403	Long-lasting sport practice and lone atrial fibrillation. European Heart Journal, 2002, 23, 477-482.	2.2	293
404	Low recurrence of syncope in patients with inducible sustained ventricular tachyarrhythmias treated with an implantable cardioverter-defibrillator. European Heart Journal, 2002, 23, 901-907.	2.2	20
405	Accessory Pathway Localization by QRS Polarity in Children with Wolff-Parkinson-White Syndrome. Journal of Cardiovascular Electrophysiology, 2002, 13, 1222-1226.	1.7	65
406	Inappropriate Tachycardia Detection by a Biventricular Implantable Cardioverter Defibrillator. PACE - Pacing and Clinical Electrophysiology, 2002, 25, 123-124.	1.2	29
407	Coronary artery revascularization in patients with sustained ventricular arrhythmias in the chronic phase of a myocardial infarction: effects on the electrophysiologic substrate and outcome. Journal of the American College of Cardiology, 2001, 37, 529-533.	2.8	103
408	Prognostic Value of Electrophysiologic Investigations in Brugada Syndrome. Journal of Cardiovascular Electrophysiology, 2001, 12, 1004-1007.	1.7	142
409	Outcomes after radiofrequency catheter ablation of atrial tachycardia. American Journal of Cardiology, 2001, 87, 886-890.	1.6	60
410	Radiofrequency Ablation of a Posteroseptal Atrioventricular Accessory Pathway in a Left-Sided Tricuspid Ring with Ebsteinlike Anomaly in a Patient with Congenitally Corrected Transposition of the Great Arteries. PACE - Pacing and Clinical Electrophysiology, 2000, 23, 133-136.	1.2	26
411	Arrhythmia recurrence in patients with a healed myocardial infarction who received an implantable defibrillator: analysis according to the clinical presentation. Journal of the American College of Cardiology, 1999, 34, 351-357.	2.8	23
412	Radiofrequency Ablation of Anteroseptal, Para-Hisian, and Mid-Septal Accessory Pathways Using a Simplified Femoral Approach. PACE - Pacing and Clinical Electrophysiology, 1998, 21, 735-741.	1.2	38
413	Enhanced Detection Criteria in Implantable Defibrillators. Journal of Cardiovascular Electrophysiology, 1998, 9, 261-268.	1.7	112
414	Hypertrophic Cardiomyopathy: Role of the Implantable Cardioverter-Defibrillator. Journal of the American College of Cardiology, 1998, 31, 1081-1085.	2.8	63

#	Article	IF	Citations
415	Identification of a Genetic Locus for Familial Atrial Fibrillation. New England Journal of Medicine, 1997, 336, 905-911.	27.0	533
416	Local Repolarization Abnormalities Induced by Transcatheter Radiofrequency Ablation in Pigs. PACE - Pacing and Clinical Electrophysiology, 1997, 20, 1952-1960.	1.2	4
417	Atrial Fibrillation Induced by Atrioventricular Nodal Reentrant Tachycardia. American Journal of Cardiology, 1997, 79, 681-682.	1.6	46
418	Predisposing Factors and Prognostic Value of Sustained Monomorphic Ventricular Tachycardia in the Early Phase of Acute Myocardial Infarction. Journal of the American College of Cardiology, 1996, 28, 1670-1676.	2.8	77
419	Coronary denervation attenuates coronary constriction induced by muscarinic receptor stimulation in pigs. Cardiovascular Research, 1996, 32, 311-319.	3.8	2
420	Limitations of head-up tilt test for evaluating the efficacy of therapeutic interventions in patients with vasovagal syncope: Results of a controlled study of etilefrine versus placebo. Journal of the American College of Cardiology, 1995, 25, 65-69.	2.8	143
421	The electrocardiographic, clinical, and electrophysiologic spectrum of idiopathic monomorphic ventricular tachycardia. American Heart Journal, 1992, 124, 746-753.	2.7	50
422	Incidence, pathophysiology and prognosis of exercise-induced sustained ventricular tachycardia associated with healed myocardial infarction. American Journal of Cardiology, 1992, 70, 875-878.	1.6	8
423	Mechanisms of Sudden Cardiac Death. Drugs, 1991, 41, 16-23.	10.9	2
424	Clinical and electrophysiologic characteristics of exercise-related idiopathic ventricular tachycardia. American Journal of Cardiology, 1991, 68, 897-900.	1.6	68
425	Significance of Q-wave regression after transmural acute myocardial infarction. American Journal of Cardiology, 1988, 61, 739-742.	1.6	40
426	A Novel Biomarker Model for Detecting Patients With Atrial Fibrillation: A Development and Validation Study. SSRN Electronic Journal, 0, , .	0.4	0
427	Developments in imaging tools for AF. , 0, , .		0